Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Scientists at the McGovern Institute and the Broad Institute of MIT and Harvard have reengineered a compact RNA-guided enzyme ...

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving ...

The slice of code — a stretch of DNA that acts like a dial to turn up the expression of certain genes — expanded the outer ...

Trust of our neighbors is increasingly required to our shared human experience.

Danforth Technology Company launched Spearhead Bio to make the process of gene editing faster and more efficient.

Fidelity Select Biotechnology Portfolio earns an Average Process Pillar rating. The primary contributor to the rating is its parent firm's excellent long-term risk-adjusted performance ...

Fidelity Advisor Biotechnology Fund earns an Average Process Pillar rating. The leading factor in the rating is its parent firm's superior long-term risk-adjusted performance, as shown by the firm ...

For instance, one study of 458 pharmaceutical and biotechnology license agreements found a 7% average royalty. That is attractive as a simple option, but it also ignores the investments and risks ...